Covered recipient · General Payments record
REBECCA JONES
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$18,476.30
244 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,627.54 | 5 |
| Food and Beverage | $4,848.76 | 239 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| BANNER LIFE SCIENCES, LLC | $13,938.79 | 35 |
| ABBVIE INC. | $874.92 | 45 |
| Alexion Pharmaceuticals, Inc. | $486.10 | 11 |
| Novartis Pharmaceuticals Corporation | $469.29 | 29 |
| TG Therapeutics, Inc. | $305.76 | 9 |
| UCB, Inc. | $241.06 | 10 |
| PFIZER INC. | $213.88 | 14 |
| Celgene Corporation | $212.58 | 11 |
| Biogen, Inc. | $202.38 | 14 |
| Genentech USA, Inc. | $186.89 | 6 |
| Teva Pharmaceuticals USA, Inc. | $172.16 | 8 |
| Eisai Inc. | $159.44 | 7 |
| Lilly USA, LLC | $136.96 | 10 |
| Amneal Pharmaceuticals LLC | $133.82 | 8 |
| ARGENX US, INC. | $118.02 | 4 |
| GENZYME CORPORATION | $110.86 | 1 |
| Neurocrine Biosciences, Inc. | $97.14 | 3 |
| Ipsen Biopharmaceuticals, Inc | $80.25 | 3 |
| ACADIA Pharmaceuticals Inc | $70.77 | 3 |
| EMD Serono, Inc. | $66.31 | 3 |
| Acorda Therapeutics, Inc | $42.99 | 2 |
| Merz Pharmaceuticals, LLC | $24.15 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.86 | 1 |
| Lundbeck LLC | $21.31 | 1 |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $20.59 | 1 |
| CATALYST PHARMACEUTICALS, INC. | $19.55 | 1 |
| Sumitomo Pharma America, Inc. | $16.89 | 1 |
| Vanda Pharmaceuticals Inc. | $16.43 | 1 |
| NEUROPACE, INC. | $15.15 | 1 |
Page 5 of 5; records 201–244 of 244 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
REBECCA JONES
NPI 1104260819 · CMS profile ID 593769
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
PHOENIX, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 5; records 201–244 of 244 matching records. This page contains 44 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1104260819?year=2024&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- REBECCA JONES, NPI 1104260819, CMS profile ID 593769. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–244 of 244 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104260819?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). REBECCA JONES, NPI 1104260819, CMS profile ID 593769. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–244 of 244 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104260819?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- REBECCA JONES, NPI 1104260819, CMS profile ID 593769, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–244 of 244 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1104260819?year=2024&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
244 matching records · $18,476.30 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–244 of 244.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| BANNER LIFE SCIENCES, LLC | $7.25 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147028932 | CMS |
| BANNER LIFE SCIENCES, LLC | $7.24 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147028934 | CMS |
| Biogen, Inc. | $20.29 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104827550 | CMS |
| Novartis Pharmaceuticals Corporation | $6.78 | 03/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087020428 | CMS |
| Teva Pharmaceuticals USA, Inc. | $13.41 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151612032 | CMS |
| ABBVIE INC. | $4.95 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104009164 | CMS |
| Genentech USA, Inc. | $33.05 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133094473 | CMS |
| Alexion Pharmaceuticals, Inc. | $29.05 | 02/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1093894326 | CMS |
| EMD Serono, Inc. | $14.53 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120232566 | CMS |
| Novartis Pharmaceuticals Corporation | $16.70 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087020426 | CMS |
| Ipsen Biopharmaceuticals, Inc | $33.24 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091968217 | CMS |
| PFIZER INC. | $26.67 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131153672 | CMS |
| Alexion Pharmaceuticals, Inc. | $113.94 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1093950691 | CMS |
| ABBVIE INC. | $1.42 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104009160 | CMS |
| ABBVIE INC. | $35.00 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104009162 | CMS |
| Lundbeck LLC | $21.31 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145929848 | CMS |
| ABBVIE INC. | $4.50 | 02/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104009158 | CMS |
| Acorda Therapeutics, Inc | $23.38 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142349644 | CMS |
| Amneal Pharmaceuticals LLC | $21.53 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139190442 | CMS |
| TG Therapeutics, Inc. | $9.12 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136872011 | CMS |
| Teva Pharmaceuticals USA, Inc. | $29.69 | 02/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151612022 | CMS |
| Biogen, Inc. | $27.38 | 02/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104824174 | CMS |
| ABBVIE INC. | $27.40 | 02/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104009156 | CMS |
| Alexion Pharmaceuticals, Inc. | $31.95 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1094017282 | CMS |
| BANNER LIFE SCIENCES, LLC | $19.60 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147028596 | CMS |
| Genentech USA, Inc. | $33.05 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133094457 | CMS |
| Novartis Pharmaceuticals Corporation | $22.60 | 02/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087020422 | CMS |
| PFIZER INC. | $20.15 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131153668 | CMS |
| Novartis Pharmaceuticals Corporation | $24.93 | 01/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087020420 | CMS |
| NEUROPACE, INC. | $15.15 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153275410 | CMS |
| Acorda Therapeutics, Inc | $19.61 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142349646 | CMS |
| UCB, Inc. | $29.66 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143065869 | CMS |
| Amneal Pharmaceuticals LLC | $16.37 | 01/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139190440 | CMS |
| ABBVIE INC. | $10.70 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104009154 | CMS |
| Lilly USA, LLC | $15.05 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135372716 | CMS |
| Alexion Pharmaceuticals, Inc. | $88.05 | 01/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1093957096 | CMS |
| Novartis Pharmaceuticals Corporation | $26.11 | 01/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087020418 | CMS |
| UCB, Inc. | $28.04 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143065867 | CMS |
| ABBVIE INC. | $25.10 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104009152 | CMS |
| ABBVIE INC. | $32.83 | 01/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104009150 | CMS |
| Alexion Pharmaceuticals, Inc. | $30.38 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1094014102 | CMS |
| ABBVIE INC. | $24.29 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104009148 | CMS |
| Teva Pharmaceuticals USA, Inc. | $25.39 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151612006 | CMS |
| PFIZER INC. | $8.91 | 01/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131814150 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $417,629.90 | 36 |
| PY2024 | Principal investigator | $606,667.56 | 25 |
| PY2023 | Principal investigator | $4,742.20 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
36 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | TG Therapeutics, Inc. | $5,895.00 | 11/30/2025 | Non-covered Recipient Entity Arizona Neuroscience Research, LLC. | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200239 |
| Principal investigator 1 | Genentech, Inc. | $2,748.00 | 11/25/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211573431 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,470.00 | 11/01/2025 | Non-covered Recipient Entity Arizona Neuroscience Research, LLC. | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200237 |
| Principal investigator 1 | SK Life Science, Inc. | $500.00 | 10/08/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH | YKP3089C049 | No dispute reported | 06/30/2026 | 1252275847 |
| Principal investigator 1 | SK Life Science, Inc. | $2,000.00 | 10/08/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH | YKP3089C049 | No dispute reported | 06/30/2026 | 1252275849 |
| Principal investigator 1 | SK Life Science, Inc. | $17,750.00 | 10/08/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH | YKP3089C049 | No dispute reported | 06/30/2026 | 1252275851 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,470.00 | 09/30/2025 | Non-covered Recipient Entity Arizona Neuroscience Research, LLC. | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200209 |
| Principal investigator 1 | Genentech, Inc. | $9,198.90 | 09/19/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211573274 |
| Principal investigator 1 | GENZYME CORPORATION | $27,218.00 | 09/03/2025 | Non-covered Recipient Entity Arizona Neuroscience Research Llc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226116749 |
| Principal investigator 1 | Genentech, Inc. | $2,389.00 | 08/21/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211573427 |
| Principal investigator 1 | SK Life Science, Inc. | $1,417.60 | 08/15/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH | YKP3089C049 | No dispute reported | 06/30/2026 | 1252275837 |
| Principal investigator 1 | Genentech, Inc. | $103.00 | 07/11/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211573286 |
| Principal investigator 1 | Genentech, Inc. | $1,020.40 | 07/11/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211573293 |
| Principal investigator 1 | Genentech, Inc. | $56.00 | 07/09/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211573283 |
| Principal investigator 1 | Genentech, Inc. | $6,826.00 | 07/09/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211573289 |
| Principal investigator 1 | Genentech, Inc. | $103.00 | 07/01/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211573269 |
| Principal investigator 1 | Genentech, Inc. | $16,960.60 | 07/01/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211573278 |
| Principal investigator 1 | SK Life Science, Inc. | $1,417.60 | 06/18/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH | YKP3089C049 | No dispute reported | 06/30/2026 | 1252275791 |
| Principal investigator 1 | TG Therapeutics, Inc. | $8,240.00 | 06/01/2025 | Non-covered Recipient Entity Arizona Neuroscience Research, LLC. | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200173 |
| Principal investigator 1 | Genentech, Inc. | $13,409.59 | 05/28/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211573419 |
| Principal investigator 1 | SK Life Science, Inc. | $2,417.70 | 05/23/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH | YKP3089C049 | No dispute reported | 06/30/2026 | 1252275789 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $54,002.67 | 05/22/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190312069 |
| Principal investigator 1 | Genentech, Inc. | $2,689.00 | 05/21/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211573415 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,470.00 | 05/01/2025 | Non-covered Recipient Entity Arizona Neuroscience Research, LLC. | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200171 |
| Principal investigator 1 | Genentech, Inc. | $1,340.00 | 04/30/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211573261 |
| Principal investigator 1 | GENZYME CORPORATION | $30,505.37 | 04/21/2025 | Non-covered Recipient Entity Arizona Neuroscience Research Llc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226116732 |
| Principal investigator 1 | Genentech, Inc. | $7,260.30 | 04/17/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211573265 |
| Principal investigator 1 | GENZYME CORPORATION | $4,892.00 | 04/07/2025 | Non-covered Recipient Entity Arizona Neuroscience Research Llc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226116719 |
| Principal investigator 1 | Genentech, Inc. | $2,389.00 | 04/02/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH LLC | Evaluation of Fenebrutinib in RMS patients | No dispute reported | 06/30/2026 | 1211573423 |
| Principal investigator 1 | TG Therapeutics, Inc. | $5,365.76 | 02/28/2025 | Non-covered Recipient Entity Arizona Neuroscience Research, LLC. | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200187 |
| Principal investigator 1 | GENZYME CORPORATION | $6,209.00 | 02/24/2025 | Non-covered Recipient Entity Arizona Neuroscience Research Llc | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226116711 |
| Principal investigator 1 | SK Life Science, Inc. | $21,500.00 | 02/19/2025 | Non-covered Recipient Entity ARIZONA NEUROSCIENCE RESEARCH | YKP3089C049 | No dispute reported | 06/30/2026 | 1252275823 |
| Principal investigator 1 | TG Therapeutics, Inc. | $940.00 | 02/01/2025 | Non-covered Recipient Entity Arizona Neuroscience Research, LLC. | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200169 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $111,311.16 | 01/31/2025 | Non-covered Recipient Entity CENTER FOR NEUROLOGY AND SPINE | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190312673 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $40,145.25 | 01/07/2025 | Non-covered Recipient Entity HOPE RESEARCH INSTITUTE | AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes | No dispute reported | 06/30/2026 | 1190304169 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,000.00 | 01/06/2025 | Non-covered Recipient Entity Arizona Neuroscience Research, LLC. | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200189 |